---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-286790"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2023-12-01T23:59:59+00:00"
generated_at: "2026-06-07T19:27:30.913687+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cyclerion appoints Michael Higgins and Dina Katabi to Board of Directors; board expands to six members.

## Summary
- Board increased to six members; Higgins and Katabi elected effective Nov 30, 2023, both deemed independent under NASDAQ rules.
- Higgins appointed Audit Committee Chair; Katabi appointed to Nominating and Corporate Governance Committee.
- Higgins is Voyager Therapeutics Chairman and former Ironwood COO; Katabi is MIT professor, MacArthur Fellow, and co-founder of Emerald Innovations.
- Compensation: each receives $12,000 cash retainer and 20,000 restricted stock units vesting over 42 months.
- Press release signals board refresh to explore possible licenses, mergers, acquisitions, or other investments.

## SEC filing metadata
- accession: 0001193125-23-286790
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2023-12-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000119312523286790/0001193125-23-286790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000119312523286790/d559453d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-286790
- JSON: https://secwatch.observer/filing/0001193125-23-286790.json
- Plain text: https://secwatch.observer/filing/0001193125-23-286790.txt

## Key facts
- Executive change
  Michael Higgins was elected as Director at Cyclerion Therapeutics, Inc..
  - Action: elected
  - Role: Director
  source text: On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000119312523286790/0001193125-23-286790-index.htm
- Executive change
  Dina Katabi was elected as Director at Cyclerion Therapeutics, Inc..
  - Action: elected
  - Role: Director
  source text: On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000119312523286790/0001193125-23-286790-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.